Pancreatic Cancer Research

ResearcherBroad InstituteActive in the last 2 years

A. Cole Edwards

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9220-9642; OpenAlex author ID A5004033177, A5128909592; NIH RePORTER profile ID 16052067. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
1
Labs led
0
Collaborators
34
Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper · 2023: 1 grant · 2024: 2 papers · 2025: 2 papers · 2026: 3 papers

Papers 9

  1. Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. Co-author DOI 10.1016/j.celrep.2026.117627↗
  2. Cancer interception with KRAS inhibitors in preclinical models of pancreatic ductal adenocarcinoma. Co-author DOI 10.1126/science.aec7929↗
  3. CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-1835↗
  4. Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer. Co-author DOI 10.1126/scisignal.adu7145↗
  5. p53 and YAP/TAZ-TEAD activities determine metaplastic heterogeneity in pancreatic cancer Co-author DOI 10.64898/2025.12.11.693520↗
  6. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Co-author DOI 10.1038/s41586-024-07379-z↗
  7. Author Correction: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Co-author DOI 10.1038/s41586-024-08084-7↗
  8. Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors. Co-author DOI 10.1158/0008-5472.can-21-1443↗
  9. Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. Co-author DOI 10.1016/j.celrep.2021.109291↗

Grants 1

  1. Mechanisms of YAP1-driven resistance to KRAS-G12C inhibition F31CA275260↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Channing J. Der · 6 shared papers, 2021–2026 · strength 1.05
  2. Adrienne D. Cox · 5 shared papers, 2021–2026 · strength 0.80
  3. Clint A. Stalnecker · 5 shared papers, 2021–2026 · strength 0.80
  4. Andrew M. Waters · 4 shared papers, 2021–2026 · strength 0.67
  5. Craig M. Goodwin · 4 shared papers, 2021–2026 · strength 0.62
  6. Kirsten L. Bryant · 3 shared papers, 2022–2026 · strength 0.52
  7. Andrew J. Aguirre · 3 shared papers, 2021–2026 · strength 0.49
  8. G. Aaron Hobbs · 3 shared papers, 2021–2026 · strength 0.49
  9. J. Nathaniel Diehl · 3 shared papers, 2021–2026 · strength 0.46
  10. Priya S. Hibshman · 3 shared papers, 2021–2026 · strength 0.46
  11. Lee M. Graves · 3 shared papers, 2021–2026 · strength 0.46
  12. Jennifer E. Klomp · 3 shared papers, 2021–2026 · strength 0.46
  13. Bjoern Papke · 3 shared papers, 2021–2026 · strength 0.40
  14. Mariaelena Pierobon · 2 shared papers, 2022–2025 · strength 0.31
  15. Devon R. Blake · 2 shared papers, 2021–2026 · strength 0.28
  16. William C. Hahn · 2 shared papers, 2021–2026 · strength 0.28
  17. Tikvah K. Hayes · 2 shared papers, 2021–2026 · strength 0.28
  18. John P. Morris · 1 shared paper, 2025 · strength 0.26
  19. Cole P Martin · 1 shared paper, 2025 · strength 0.26
  20. Minh T. Than · 1 shared paper, 2026 · strength 0.23
  21. Ben Z. Stanger · 1 shared paper, 2026 · strength 0.23
  22. Robert H. Vonderheide · 1 shared paper, 2026 · strength 0.23
  23. Ashley L. Kiemen · 1 shared paper, 2026 · strength 0.23
  24. Szu-Aun Lim · 1 shared paper, 2026 · strength 0.21
  25. Julien Dilly · 1 shared paper, 2026 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.